Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0OA3L
|
|||
Former ID |
DIB021195
|
|||
Drug Name |
VU0469650
|
|||
Synonyms |
3-[(3R)-3-methyl-4-[(4-methyladamantan-1-yl)carbonyl]piperazin-1-yl]pyridine-2-carbonitrile; VU0469650; GTPL6337
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL
|
|||
Formula |
C23H30N4O
|
|||
Canonical SMILES |
CC1CN(CCN1C(=O)C23CC4CC(C2)C(C(C4)C3)C)C5=C(N=CC=C5)C#N
|
|||
InChI |
1S/C23H30N4O/c1-15-14-26(21-4-3-5-25-20(21)13-24)6-7-27(15)22(28)23-10-17-8-18(11-23)16(2)19(9-17)12-23/h3-5,15-19H,6-12,14H2,1-2H3/t15-,16?,17?,18?,19?,23?/m1/s1
|
|||
InChIKey |
HPOKCTFUFZGTGF-ABYMYHKNSA-N
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Metabotropic glutamate receptor 1 (mGluR1) | Target Info | Modulator (allosteric modulator) | [1] |
KEGG Pathway | Calcium signaling pathway | |||
FoxO signaling pathway | ||||
Neuroactive ligand-receptor interaction | ||||
Gap junction | ||||
Long-term potentiation | ||||
Retrograde endocannabinoid signaling | ||||
Glutamatergic synapse | ||||
Long-term depression | ||||
Estrogen signaling pathway | ||||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||
Metabotropic glutamate receptor group III pathway | ||||
Metabotropic glutamate receptor group I pathway | ||||
Endogenous cannabinoid signaling | ||||
Reactome | G alpha (q) signalling events | |||
Class C/3 (Metabotropic glutamate/pheromone receptors) | ||||
WikiPathways | Hypothetical Network for Drug Addiction | |||
GPCRs, Class C Metabotropic glutamate, pheromone | ||||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
GPCR ligand binding | ||||
GPCR downstream signaling | ||||
GPCRs, Other |
References | Top | |||
---|---|---|---|---|
REF 1 | N-Acyl-N'-arylpiperazines as negative allosteric modulators of mGlu1: identification of VU0469650, a potent and selective tool compound with CNS exposure in rats. Bioorg Med Chem Lett. 2013 Jul 1;23(13):3713-8. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.